<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<oembed>
  <author_name>a-radion-note</author_name>
  <author_url>https://blog.hatena.ne.jp/a-radion-note/</author_url>
  <blog_title>放射線治療医　海野しおんの雑記帳</blog_title>
  <blog_url>https://uminoshion.hatenablog.com/</blog_url>
  <categories>
    <anon>膵がん</anon>
    <anon>切除可能膵がん</anon>
    <anon>切除可能境界膵がん</anon>
    <anon>術前化学療法</anon>
    <anon>体幹部定位放射線治療</anon>
  </categories>
  <description>Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma: An Academic Gastrointestinal Cancer Consortium (AGICC) Study.Cohen DJ, Goldberg JD, Leichman L, et al. Oncologist. 2025 Sep 16:oyaf271. doi: 10.1093/oncolo/oyaf271. Epub ahead of print. PMID: 40972532. 【概要】・切除可…</description>
  <height>190</height>
  <html>&lt;iframe src=&quot;https://hatenablog-parts.com/embed?url=https%3A%2F%2Fuminoshion.hatenablog.com%2Fentry%2F2025%2F09%2F21%2F142611&quot; title=&quot;【多施設共同第II相試験】切除可能/切除可能境界膵がんに対する術前化学療法（GEM＋nab-PTX）＋ 体幹部定位放射線治療（SBRT） - 放射線治療医　海野しおんの雑記帳&quot; class=&quot;embed-card embed-blogcard&quot; scrolling=&quot;no&quot; frameborder=&quot;0&quot; style=&quot;display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;&quot;&gt;&lt;/iframe&gt;</html>
  <image_url></image_url>
  <provider_name>Hatena Blog</provider_name>
  <provider_url>https://hatena.blog</provider_url>
  <published>2025-09-21 14:26:11</published>
  <title>【多施設共同第II相試験】切除可能/切除可能境界膵がんに対する術前化学療法（GEM＋nab-PTX）＋ 体幹部定位放射線治療（SBRT）</title>
  <type>rich</type>
  <url>https://uminoshion.hatenablog.com/entry/2025/09/21/142611</url>
  <version>1.0</version>
  <width>100%</width>
</oembed>
